Zavegepant
Clinical data
Trade namesZavzpret
Other namesBHV-3500
License data
Routes of
administration		Nasal
Drug classCalcitonin gene-related peptide receptor antagonist
ATC code
  • None
Legal status
Legal status
Identifiers
  • N-[(2R)-3-(7-methyl-1H-indazol-5-yl)-1-[4-(1-methylpiperidin-4-yl)piperazin-1-yl]-1-oxopropan-2-yl]-4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxamide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
Chemical and physical data
FormulaC36H46N8O3
Molar mass638.817 g·mol−1
3D model (JSmol)
  • CC1=CC(=CC2=C1NN=C2)CC(C(=O)N3CCN(CC3)C4CCN(CC4)C)NC(=O)N5CCC(CC5)C6=CC7=CC=CC=C7NC6=O
  • InChI=1S/C36H46N8O3/c1-24-19-25(20-28-23-37-40-33(24)28)21-32(35(46)43-17-15-42(16-18-43)29-9-11-41(2)12-10-29)39-36(47)44-13-7-26(8-14-44)30-22-27-5-3-4-6-31(27)38-34(30)45/h3-6,19-20,22-23,26,29,32H,7-18,21H2,1-2H3,(H,37,40)(H,38,45)(H,39,47)/t32-/m1/s1
  • Key:JJVAPHYEOZSKJZ-JGCGQSQUSA-N
  • Key:VQDUWCSSPSOSNA-RYWNGCACSA-N

Zavegepant, sold under the brand name Zavzpret, is a medication used for the treatment of migraine.[1] Zavegepant is a calcitonin gene-related peptide receptor antagonist.[1] It is sprayed into the nose.[1] It is sold by Pfizer.[1]

The most common adverse reactions include taste disorders, nausea, nasal discomfort, and vomiting.[1]

Zavegepant was approved for medical use in the United States in March 2023.[1][2][3][4]

Medical uses

Zavegepant is indicated for the acute treatment of migraine with or without aura in adults.[1][5][6]

References

  1. ^ a b c d e f g h "Zavzpret- zavegepant spray". DailyMed. 9 March 2023. Retrieved 25 August 2023.
  2. ^ "Drug Approval Package: Zavzpret". U.S. Food and Drug Administration (FDA). 3 April 2023. Retrieved 25 August 2023.
  3. ^ "Pfizer's Zavzpret (Zavegepant) Migraine Nasal Spray Receives FDA Approval" (Press release). 10 March 2023.
  4. ^ Dhillon S (June 2023). "Zavegepant: First Approval". Drugs. 83 (9): 825–831. doi:10.1007/s40265-023-01885-6. PMC 10209931. PMID 37227596.
  5. ^ Khan ZZ, Ahmed U, Shahzad F, Ali M, Tousif K, Ahmed U, et al. (July 2023). "Safety and Efficacy of Zavegepant in Treating Migraine: A Systematic Review". Cureus. 15 (7): e41991. doi:10.7759/cureus.41991. PMC 10428082. PMID 37593294.
  6. ^ Martirosov AL, Giuliano C, Shupp M, Channey S, Kale-Pradhan PB (October 2023). "Zavegepant Intranasal Spray for Migraines". The Annals of Pharmacotherapy: 10600280231209439. doi:10.1177/10600280231209439. PMID 37897226. S2CID 264543368.

Further reading

External links


Antimigraine preparations (N02C)
More
Categories